---
document_datetime: 2025-12-02 06:51:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/targretin.html
document_name: targretin.html
version: success
processing_time: 0.113345
conversion_datetime: 2025-12-28 03:25:28.4806
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Targretin

[RSS](/en/individual-human-medicine.xml/65435)

##### Authorised

This medicine is authorised for use in the European Union

bexarotene Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Targretin](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Targretin is a cancer medicine used for the treatment of the visible signs on the skin of cutaneous T-cell lymphoma (CTCL). CTCL is a rare type of lymphoma (cancer of the lymph tissue) where some white blood cells (T-cells) grow in the skin. Targretin is used in patients who have an advanced disease and have had at least one other treatment.

Expand section

Collapse section

## How is Targretin used?

Targretin can only be obtained with a prescription and treatment should only be initiated and maintained by a doctor who has experience in the treatment of patients with CTCL.

Targretin is available as capsules (75 mg). The dose of Targretin is based on the patient's body surface area in square metres (m 2 ). The recommended starting dose is 300 mg/m 2 /day, taken as a single dose once a day with a meal. The dose is adjusted depending on the patient's response to treatment or side effects. Treatment should continue as long as the patient benefits from it.

For more information about using Targretin, see the package leaflet or contact your doctor or pharmacist.

## How does Targretin work?

The active substance in Targretin, bexarotene, belongs to the group of retinoids, substances that are derived from vitamin A. The exact way bexarotene works in CTCL is not known.

## What benefit of Targretin have been shown in studies?

The effectiveness of Targretin has been examined in two studies involving a total of 193 patients with CTCL who received at least two previous treatments. Targretin was not compared with another medicine. Ninety-three of these patients had advanced disease that had not responded to other treatment. Sixty-one patients were treated at the starting dose of 300 mg/m 2 /day. The main measure of effectiveness was the response to treatment after 16 weeks. This was measured by the doctor's grading of improvement, as well as by a score of 5 clinical signs (area of skin affected, redness, raised areas, scale-like skin and colour).

Across the two studies, among the patients who received 300 mg/m 2 , about half of them responded to treatment, according the doctor's grading. The response rates according to the 5 skin scores were 36% and 27%, respectively.

## What are the risks associated with Targretin?

The most common side effects with Targretin (which may affect more than 1 patient in 10) are leucopenia (reduced white cell count), hypothyroidism (underactive thyroid gland), hyperlipaemia (high levels of fats in the blood), hypercholesterolaemia (high blood cholesterol), exfoliative dermatitis (skin peeling), pruritus (itching), rash, pain, headache and weakness. For the full list of side effects reported with Targretin, see the package leaflet.

Targretin must not be used in women who are pregnant or breast-feeding, or women who could become pregnant and who are not using effective contraception; patients who have had pancreatitis (inflammation of the pancreas); patients with uncontrolled hypercholesterolaemia (high blood cholesterol), hypertriglyceridaemia (high blood triglycerides [fat]) or thyroid disease; patients with hypervitaminosis A (high levels of vitamin A); patients with liver disease; patients with an ongoing body infection. For the full list of restrictions, see the package leaflet.

## Why is Targretin authorised in the EU?

The European Medicines Agency decided that Targretin's benefits are greater than its risks for the treatment of the skin manifestations of advanced-stage CTCL patients refractory to at least one treatment. The Agency recommended that Targretin be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Targretin?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Targretin have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Targretin are continuously monitored. Side effects reported with Targretin are carefully evaluated and any necessary action taken to protect patients.

## Other information about Targretin

Targretin received a marketing authorisation valid throughout the EU on 29 March 2001.

Targretin : EPAR - Medicine overview

English (EN) (74.6 KB - PDF)

**First published:** 20/04/2009

**Last updated:** 28/06/2018

[View](/en/documents/overview/targretin-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-932)

български (BG) (100.03 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/bg/documents/overview/targretin-epar-medicine-overview_bg.pdf)

español (ES) (75.4 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/es/documents/overview/targretin-epar-medicine-overview_es.pdf)

čeština (CS) (98.58 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/cs/documents/overview/targretin-epar-medicine-overview_cs.pdf)

dansk (DA) (73.27 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/da/documents/overview/targretin-epar-medicine-overview_da.pdf)

Deutsch (DE) (76.38 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/de/documents/overview/targretin-epar-medicine-overview_de.pdf)

eesti keel (ET) (73.38 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/et/documents/overview/targretin-epar-medicine-overview_et.pdf)

ελληνικά (EL) (108.56 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/el/documents/overview/targretin-epar-medicine-overview_el.pdf)

français (FR) (75.75 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/fr/documents/overview/targretin-epar-medicine-overview_fr.pdf)

hrvatski (HR) (91.97 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/hr/documents/overview/targretin-epar-medicine-overview_hr.pdf)

italiano (IT) (73.75 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/it/documents/overview/targretin-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (102.64 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/lv/documents/overview/targretin-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (96.91 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/lt/documents/overview/targretin-epar-medicine-overview_lt.pdf)

magyar (HU) (93.2 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/hu/documents/overview/targretin-epar-medicine-overview_hu.pdf)

Malti (MT) (98.85 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/mt/documents/overview/targretin-epar-medicine-overview_mt.pdf)

Nederlands (NL) (74.58 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/nl/documents/overview/targretin-epar-medicine-overview_nl.pdf)

polski (PL) (99.11 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/pl/documents/overview/targretin-epar-medicine-overview_pl.pdf)

português (PT) (74.19 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/pt/documents/overview/targretin-epar-medicine-overview_pt.pdf)

română (RO) (95.31 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/ro/documents/overview/targretin-epar-medicine-overview_ro.pdf)

slovenčina (SK) (97.6 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/sk/documents/overview/targretin-epar-medicine-overview_sk.pdf)

slovenščina (SL) (92.5 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/sl/documents/overview/targretin-epar-medicine-overview_sl.pdf)

Suomi (FI) (73.33 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/fi/documents/overview/targretin-epar-medicine-overview_fi.pdf)

svenska (SV) (73.46 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

28/06/2018

[View](/sv/documents/overview/targretin-epar-medicine-overview_sv.pdf)

## Product information

Targretin : EPAR - Product Information

English (EN) (286.02 KB - PDF)

**First published:** 20/04/2009

**Last updated:** 12/08/2025

[View](/en/documents/product-information/targretin-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-67)

български (BG) (390.05 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/bg/documents/product-information/targretin-epar-product-information_bg.pdf)

español (ES) (302.95 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/es/documents/product-information/targretin-epar-product-information_es.pdf)

čeština (CS) (389.98 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/cs/documents/product-information/targretin-epar-product-information_cs.pdf)

dansk (DA) (334.29 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/da/documents/product-information/targretin-epar-product-information_da.pdf)

Deutsch (DE) (398.27 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/de/documents/product-information/targretin-epar-product-information_de.pdf)

eesti keel (ET) (317.68 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/et/documents/product-information/targretin-epar-product-information_et.pdf)

ελληνικά (EL) (437.14 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/el/documents/product-information/targretin-epar-product-information_el.pdf)

français (FR) (335.03 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/fr/documents/product-information/targretin-epar-product-information_fr.pdf)

hrvatski (HR) (289.27 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/hr/documents/product-information/targretin-epar-product-information_hr.pdf)

íslenska (IS) (302.48 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/is/documents/product-information/targretin-epar-product-information_is.pdf)

italiano (IT) (302.86 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/it/documents/product-information/targretin-epar-product-information_it.pdf)

latviešu valoda (LV) (342.71 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/lv/documents/product-information/targretin-epar-product-information_lv.pdf)

lietuvių kalba (LT) (324.95 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/lt/documents/product-information/targretin-epar-product-information_lt.pdf)

magyar (HU) (322.32 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/hu/documents/product-information/targretin-epar-product-information_hu.pdf)

Malti (MT) (385.4 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/mt/documents/product-information/targretin-epar-product-information_mt.pdf)

Nederlands (NL) (306.93 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/nl/documents/product-information/targretin-epar-product-information_nl.pdf)

norsk (NO) (311.54 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/no/documents/product-information/targretin-epar-product-information_no.pdf)

polski (PL) (313.74 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/pl/documents/product-information/targretin-epar-product-information_pl.pdf)

português (PT) (320.25 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/pt/documents/product-information/targretin-epar-product-information_pt.pdf)

română (RO) (306.84 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/ro/documents/product-information/targretin-epar-product-information_ro.pdf)

slovenčina (SK) (316.7 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/sk/documents/product-information/targretin-epar-product-information_sk.pdf)

slovenščina (SL) (302.69 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/sl/documents/product-information/targretin-epar-product-information_sl.pdf)

Suomi (FI) (307.03 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/fi/documents/product-information/targretin-epar-product-information_fi.pdf)

svenska (SV) (298.2 KB - PDF)

**First published:**

20/04/2009

**Last updated:**

12/08/2025

[View](/sv/documents/product-information/targretin-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000291441 11/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Targretin : EPAR - All Authorised presentations

English (EN) (57.24 KB - PDF)

**First published:** 08/08/2006

**Last updated:** 08/08/2006

[View](/en/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-903)

български (BG) (81.88 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/bg/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_bg.pdf)

español (ES) (58.39 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/es/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_es.pdf)

čeština (CS) (78.97 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/cs/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (60.42 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/da/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (61.18 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/de/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (56.59 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/et/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (76.31 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/el/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_el.pdf)

français (FR) (57.61 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/fr/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (55.51 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/it/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (78.13 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/lv/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (68.93 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/lt/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (69.14 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/hu/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (81.8 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/mt/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (59.55 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/nl/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_nl.pdf)

polski (PL) (82.69 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/pl/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_pl.pdf)

português (PT) (57.3 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/pt/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_pt.pdf)

română (RO) (74.22 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/ro/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (69.58 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/sk/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (60.35 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/sl/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (57.55 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/fi/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (59.96 KB - PDF)

**First published:**

08/08/2006

**Last updated:**

08/08/2006

[View](/sv/documents/all-authorised-presentations/targretin-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Targretin Active substance bexarotene International non-proprietary name (INN) or common name bexarotene Therapeutic area (MeSH) Lymphoma, T-Cell, Cutaneous Anatomical therapeutic chemical (ATC) code L01XF03

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.

## Authorisation details

EMA product number EMEA/H/C/000326 Marketing authorisation holder

H.A.C. Pharma

Pericentre 2 43 Avenue De La Cote De Nacre Caen 14000 France

Opinion adopted 16/11/2000 Marketing authorisation issued 29/03/2001 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Targretin : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (254.45 KB - PDF)

**First published:** 12/05/2025

**Last updated:** 12/08/2025

[View](/en/documents/procedural-steps-after/targretin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Targretin : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (223.71 KB - PDF)

**First published:** 20/04/2009

**Last updated:** 12/05/2025

[View](/en/documents/procedural-steps-after/targretin-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Targretin-H-A-31-1446-C-000326-0043 : EPAR - Assessment Report

Adopted

Reference Number: EMA/254364/2018

English (EN) (282.63 KB - PDF)

**First published:** 28/06/2018

**Last updated:** 28/06/2018

[View](/en/documents/variation-report/targretin-h-31-1446-c-000326-0043-epar-assessment-report_en.pdf)

Targretin : EPAR - Divergent position(s) - Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data

English (EN) (38.49 KB - PDF)

**First published:** 28/06/2018

**Last updated:** 28/06/2018

[View](/en/documents/scientific-conclusion/targretin-epar-divergent-positions-article-31-directive-200183ec-resulting-pharmacovigilance-data_en.pdf)

Targretin-H-C-PSUSA-00000404-201409 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/304483/2015

English (EN) (67.43 KB - PDF)

**First published:** 21/07/2015

**Last updated:** 21/07/2015

[View](/en/documents/scientific-conclusion/targretin-h-c-psusa-00000404-201409-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Targretin : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (84.21 KB - PDF)

**First published:** 08/08/2006

**Last updated:** 08/08/2006

[View](/en/documents/steps-after-cutoff/targretin-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Targretin : EPAR - Public assessment report

English (EN) (440.29 KB - PDF)

**First published:** 16/02/2021

[View](/en/documents/assessment-report/targretin-epar-public-assessment-report_en.pdf)

Targretin : EPAR - Procedural steps taken before authorisation

English (EN) (92.87 KB - PDF)

**First published:** 08/08/2006

**Last updated:** 08/08/2006

[View](/en/documents/procedural-steps/targretin-epar-procedural-steps-taken-authorisation_en.pdf)

Targretin : EPAR - Scientific Discussion

English (EN) (363.9 KB - PDF)

**First published:** 08/08/2006

**Last updated:** 08/08/2006

[View](/en/documents/scientific-discussion/targretin-epar-scientific-discussion_en.pdf)

#### More information on Targretin

- [Retinoid-containing medicinal products - referral](/en/medicines/human/referrals/retinoid-containing-medicinal-products)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 12/08/2025

## Share this page

[Back to top](#main-content)